Keyphrases
Clinical Trials
77%
Core Outcome Set
52%
Risk-benefit
50%
Patient Benefit
49%
Patient Outcomes
49%
Drug Development
48%
Risk Outcomes
46%
Patient Risk
46%
Reporting Guidelines
38%
Clinical Trial Registry
35%
Randomized Controlled Trial
32%
Sectional Analysis
23%
Web-based Survey
16%
Trialists
15%
Adverse Events
14%
Frequently Asked Questions
12%
Objective Response Rate
11%
Google Search
11%
Meta-epidemiological Study
11%
Clinical Perspective
10%
FDA-approved Drugs
10%
Trial Registration
10%
Overall Survival
10%
Scopus
8%
Cochrane
8%
Google
8%
Patient-reported Outcomes
8%
Ramucirumab
8%
PubMed
7%
Embase
7%
Approved Indication
7%
Trial Characteristics
7%
Instructions to Authors
7%
Medical Practice
6%
Descriptive Statistics
6%
Health Research
6%
Median Progression-free Survival
6%
Progression-free Survival
5%
CiteScore
5%
Chronic Kidney Disease
5%
Cancer Clinical Trials
5%
Regorafenib
5%
Olaparib
5%
Bunion
5%
Hallux Valgus
5%
Peptic Ulcer Disease
5%
Lenvatinib
5%
Parkinson's Disease
5%
Afatinib
5%
Type I Diabetes
5%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Drug Development
48%
Randomized Controlled Trial
21%
Adverse Event
20%
Malignant Neoplasm
19%
Overall Survival
13%
Cross Sectional Study
12%
Progression Free Survival
11%
Ramucirumab
8%
Chronic Kidney Failure
5%
Lenvatinib
5%
Afatinib
5%
Regorafenib
5%
Olaparib
5%
Inflammatory Bowel Disease
5%
Lung Cancer
5%
Medicine and Dentistry
Clinical Trial
62%
Cross Sectional Study
31%
Randomized Controlled Trial
23%
Systematic Review
16%
Patient-Reported Outcome
8%
Ramucirumab
8%
Adverse Event
8%
Chronic Kidney Disease
5%
Jejunum Ulcer
5%
Osteoarthritis
5%
Olaparib
5%
Parkinson's Disease
5%
Nephrology
5%
Lung Cancer
5%
Overall Survival
5%
Malignant Neoplasm
5%
